Zacks Investment Research
22 Oct 2026, 19:35 UTC · 1h ago
Roche's 9M 2026 Sales Rise on Strong Drug Demand, Pipeline Advances
Impact · against what's priced in
Roche shows strong operational momentum with 6% constant currency growth and accelerating Q3 revenues, driven by its top five growth assets. The diversification into Diagnostics and the success of newer drugs reduce the company's reliance on legacy portfolios.
- ROG+0.50
No priced-in read yet
- In context
Sales grew 6% at constant exchange rates to CHF 46.5 billion, with Q3 growth accelerating to 8%. The top five growth drugs now generate CHF 16.8 billion, significantly diversifying the revenue base.
Read from the article alone
Top 1 mover · tap to explore
